INAVAC - UNAIR Inactivated COVID-19 Vaccine as Homologue Booster

Tahapan Penelitian : Complete
Mitra Pelaksana:
Dr. Soetomo General Academic Hospital
No Registry
Tanggal Input Registry : 07-02-2024

Humoral Immune Reponse: • SARS-CoV-2 Neutralization: SARS-CoV-2 neutralizing titers in serum measured by a virus neutralization assay, at 28 days following vaccination with INAVAC vaccine as homologue booster administered intramuscularly in healthy adults age 18 year and above • IgG RBD SARS-CoV-2 antibodies measured by CLIA: analysis of antibodies binding to the SARS-CoV-2 S-protein, at 28 days following vaccination with INAVAC vaccine as homologue booster administered intramuscularly in healthy adults age 18 year and above
Safety : • Number and percentage of subjects with solicited – clinical (local and systemic) and laboratory adverse events at 7 and 28 days, 3 and 6 months after booster vaccination. • Number and percentage of subjects with unsolicited adverse events (local and systemic) at 7 and 28 days, 3 and 6 months after booster vaccination. • Number and percentage of subjects with serious adverse events (SAE) throughout the study
INAVAC - UNAIR Inactivated COVID-19 Vaccine as Homologue Booster
Immunobridging Study: Immunogenicity and Safety of INAVAC (Vaksin Merah Putih – UNAIR SARS-CoV-2 (Vero Cell Inactivated)) Vaccine as Homologue Booster in Adult Subjects in Indonesia
INAVAC (Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg)

Inclusion Criteria:

Healthy adults and elderly, males and females, 18 years of age and above. Healthy status will be determined by the investigator based on medical history, clinical laboratory results, vital sign measurements, and physical examination at screening; Subjects already received 2 (two) doses of INAVAC vaccines (5 ug), mostly during the phase I/II/III clinical trial of this vaccine. The interval between the second primary injection and the booster is 12-18 months; Subjects have been informed properly regarding the study and signed the informed consent form; Subject will commit to comply with the instructions of the investigator and the schedule of the trial; Female subjects of childbearing potential must agree to postpone pregnancy from at least 21 days prior to enrollment and through 6 months after the vaccination; Participants agree not to donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the vaccine; Participants must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study.

Exclusion Criteria:

Subjects concomitantly enrolled or scheduled to be enrolled in another vaccine trial; Evolving mild, moderate, and severe illness, especially infectious diseases or fever (axillary temperature 37.5oC or more) concurrent or within 7 days prior to study vaccination. This includes respiratory or constitutional symptoms consistent with SARS-CoV-2 (cough, sore throat, difficulty in breathing, etc); Known history of allergy to any component of the vaccines; History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection; Any autoimmune or immunodeficiency disease/condition; Subjects who have received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulin, blood derived products, long term corticosteroid – more than 2 weeks, and so on), OR anticipation of the need for immunosuppressive treatment within 6 months after last vaccination. The use of topical or nasal steroid will be permitted. Inhaled glucocorticoids are prohibited; Unstable chronic disease, inclusive of uncontrolled hypertension, congestive heart failure, chronic obstructive pulmonary disease, asthma, chronic urticaria, diabetes requiring use of medicine. The final decision regarding this condition will be decided by the attending field clinicians or investigator; Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives; Individuals who previously receive any vaccines against Covid-19 other than INAVAC; Subjects already immunized with any other vaccines within 4 weeks prior and expect to receive other vaccines within 60 days following the booster dose; Individuals who have a previously ascertained Covid-19 in the period of 1month (for mild, moderate, or asymptomatic people) or 3 months (for severe Covid-19) before the first recruit of this study, or in a close contact in the last 14 days with confirmed case of Covid-19; Positive test for SARS-CoV-2 (Antigen or PCR) at screening prior to the vaccination. Testing may be repeated during the screening period if exposure to positive confirmed case of SARS-CoV-2 is suspected, at the discretion of investigator; History of alcohol or substance abuse; HIV patients; Malignancy patients within 3 years prior to study vaccination; Any neurological disease or history of significant neurological disorder such as meningitis, encephalitis, Guillain-Barre Syndrome, multiple sclerosis, etc; Vital sign abnormalities and clinical laboratory abnormalities as decided by the investigators. Vital sign measurements and clinical laboratory testing may be repeated before the final decision; Women who are pregnant or who plan to become pregnant during the study; Participant has major psychiatric problem or illness; Participant cannot communicate reliably with the investigator; Participant has contraindication to intramuscular injection and blood draws, such as bleeding disorders or phobia; Participant had major surgery within 12 weeks before vaccination which will not be fully recovered, or has major surgery planned during the time participant is expected to participate in the study or within 6 months after the last dose of study vaccine administration; Any condition that in the opinion of the investigators would pose a health risk to the subject if enrolled or could interfere with the evaluation of the vaccine or interpretation of the study results; Study team members; Subject planning to move from the study area before the end of study period.
Not applicable
PPUK/PPUB number
Dr. Dominicus Husada, dr., DTM&H, MCTM(TP), Sp.A(K)